Market Place
Sourcing Support
Vaxart Completes Enrollment In Phase 2b COVID-19 Oral Vaccine Study
02 Dec 2024 //
GLOBENEWSWIRE
Vaxart Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
19 Nov 2024 //
GLOBENEWSWIRE
Vaxart Business Update & Reports Q3 2024 Financial Results
13 Nov 2024 //
GLOBENEWSWIRE
Vaxart to Host Q3 2024 Financial Results & Business Update Call
07 Nov 2024 //
GLOBENEWSWIRE
Vaxart To Showcase COVID-19 And Norovirus Vaccines At Congress
24 Oct 2024 //
GLOBENEWSWIRE
Vaxart To Present Norovirus Data At IDWeek 2024
15 Oct 2024 //
GLOBENEWSWIRE
Vaxart Initiates Sentinel Cohort For Ph 2b COVID-19 Pill Vaccine
30 Sep 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Aug 2024 //
GLOBENEWSWIRE
Vaxart Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Vaxart To Host Q2 2024 Business Update Call On August 8
02 Aug 2024 //
GLOBENEWSWIRE
Vaxart provides business update
17 Jun 2024 //
GLOBENEWSWIRE
Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine
14 Jun 2024 //
ENDPTS
Vaxart Gets BARDA Award Up To $453M For COVID-19 Oral Pill Vaccine Study
13 Jun 2024 //
GLOBENEWSWIRE
Vaxart Announces $40M Underwritten Common Stock Offering
13 Jun 2024 //
GLOBENEWSWIRE
More US bird flu spread would heighten human infection risk, officials say
13 Jun 2024 //
REUTERS
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 May 2024 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Vaxart To Host Q1 2024 Business Update And Earnings Call On May 13
07 May 2024 //
GLOBENEWSWIRE
Vaxart: Positive Bivalent Norovirus Vaccine Data In Lactating Mothers
30 Apr 2024 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
27 Mar 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Mar 2024 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference
07 Mar 2024 //
GLOBENEWSWIRE
Vaxart Appoints Steven Lo as President, Chief Executive Officer, and Director
06 Mar 2024 //
GLOBENEWSWIRE
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data
05 Feb 2024 //
GLOBENEWSWIRE
Vaxart Receives $9.27 Million BARDA Project NextGen Award
19 Jan 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Announces Management Change
16 Jan 2024 //
GLOBENEWSWIRE
Vaxart Announces $10.0M Registered Direct Offering with RA Capital Management
16 Jan 2024 //
GLOBENEWSWIRE
Vaxart Announces Last Subject Dosed in Phase 1 of Norovirus Vaccine Candidate
21 Dec 2023 //
GLOBENEWSWIRE
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate
02 Nov 2023 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Vaxart to Host Third Quarter 2023 Business Update & Financial Results Conference
26 Oct 2023 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
11 Oct 2023 //
GLOBENEWSWIRE
Vaxart to Participate in Fireside Chat at 2023 Cantor Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Vaxart norovirus vaccine has mixed success in midphase test
07 Sep 2023 //
FIERCE BIOTECH
Vaxart Announces Data from Ph 2 Study of Monovalent Norovirus Vaccine Candidate
06 Sep 2023 //
GLOBENEWSWIRE
Vaxart Provides Business Update & Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Vaxart to Host Second Quarter 2023 Financial Results Conference Call on August 3
27 Jul 2023 //
GLOBENEWSWIRE
Vaxart`s oral norovirus vax spurs immune response in ph. 2 trial
06 Jul 2023 //
FIERCE BIOTECH
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Ph2 Study
06 Jul 2023 //
GLOBENEWSWIRE
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
26 Jun 2023 //
GLOBENEWSWIRE
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote
21 Jun 2023 //
GLOBENEWSWIRE
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
07 Jun 2023 //
GLOBENEWSWIRE
Vaxart Announces Subject Dosed in Phase 2 Trial of Bivalent Norovirus Candidate
06 Jun 2023 //
GLOBENEWSWIRE
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
06 Jun 2023 //
GLOBENEWSWIRE
Vaxart Launches Investor Program, First Event Scheduled for June 15 at 11 a.m.
31 May 2023 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
04 May 2023 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
29 Mar 2023 //
GLOBENEWSWIRE
Vaxart to Host Webcast with Key Opinion Leaders to Discuss Impact for Norovirus
17 Mar 2023 //
GLOBENEWSWIRE
Vaxart cans oral COVID-19 vaccine plans, lays off 27% of staff
16 Mar 2023 //
FIERCE BIOTECH
Vaxart Provides Business Update and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Vaxart Doses First Subject in the Phase 2 Trial of Bivalent Norovirus Candidate
14 Feb 2023 //
GLOBENEWSWIRE
Vaxart Names Phillip Lee as Chief Financial Officer
19 Dec 2022 //
GLOBENEWSWIRE
Vaxart Announces Collaborative Funding from Leading Foundation to Study
01 Dec 2022 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022
23 Nov 2022 //
BIOSPACE
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast
22 Nov 2022 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
08 Nov 2022 //
GLOBENEWSWIRE
Vaxart to Host Q3 2022 Business Update and Financial Results Conference
20 Oct 2022 //
GLOBENEWSWIRE
Syngene set for phase-2 trial of Covid oral tablet vaccine
12 Oct 2022 //
ECONOMIC TIMES
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
10 Oct 2022 //
GLOBENEWSWIRE
